Literature DB >> 30698710

Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis.

Amélie Vromman1, Victoria Ruvkun1, Eugenia Shvartz1, Gregory Wojtkiewicz2, Gustavo Santos Masson2, Yevgenia Tesmenitsky1, Eduardo Folco1, Hermann Gram3, Matthias Nahrendorf2, Filip K Swirski2, Galina K Sukhova1, Peter Libby1.   

Abstract

AIMS: Targeting interleukin-1 (IL-1) represents a novel therapeutic approach to atherosclerosis. CANTOS demonstrated the benefits of IL-1β neutralization in patients post-myocardial infarction with residual inflammatory risk. Yet, some mouse data have shown a prominent role of IL-1α rather than IL-1β in atherosclerosis, or even a deleterious effect of IL-1 on outward arterial remodelling in atherosclerosis-susceptible mice. To shed light on these disparate results, this study investigated the effect of neutralizing IL-1α or/and IL-1β isoforms starting either early in atherogenesis or later in ApoE-/- mice with established atheroma. METHODS AND
RESULTS: The neutralization of IL-1α or of both IL-1 isoforms impaired outward remodelling during early atherogenesis as assessed by micro-computed tomographic and histologic assessment. In contrast, the neutralization of IL-1β did not impair outward remodelling either during early atherogenesis or in mice with established lesions. Interleukin-1β inhibition promoted a slant of blood monocytes towards a less inflammatory state during atherogenesis, reduced the size of established atheromata, and increased plasma levels of IL-10 without limiting outward remodelling of brachiocephalic arteries.
CONCLUSION: This study established a pivotal role for IL-1α in the remodelling of arteries during early experimental atherogenesis, whereas IL-1β drives inflammation during atherogenesis and the evolution of advanced atheroma in mice. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Arterial remodelling; Atherosclerosis; Inflammation; Interleukin-1

Mesh:

Substances:

Year:  2019        PMID: 30698710      PMCID: PMC6685323          DOI: 10.1093/eurheartj/ehz008

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  39 in total

1.  Modulation of human cytotrophoblastic leptin secretion by interleukin-1alpha and 17beta-oestradiol and its effect on HCG secretion.

Authors:  D Chardonnens; P Cameo; M L Aubert; F P Pralong; D Islami; A Campana; R C Gaillard; P Bischof
Journal:  Mol Hum Reprod       Date:  1999-11       Impact factor: 4.025

2.  Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata.

Authors:  Filip K Swirski; Peter Libby; Elena Aikawa; Pilar Alcaide; F William Luscinskas; Ralph Weissleder; Mikael J Pittet
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  Functional significance of human vascular smooth muscle cell-derived interleukin 1 in paracrine and autocrine regulation pathways.

Authors:  H Loppnow; P Libby
Journal:  Exp Cell Res       Date:  1992-02       Impact factor: 3.905

4.  Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events.

Authors:  L M Biasucci; G Liuzzo; G Fantuzzi; G Caligiuri; A G Rebuzzi; F Ginnetti; C A Dinarello; A Maseri
Journal:  Circulation       Date:  1999-04-27       Impact factor: 29.690

5.  Shear stress-stimulated endothelial cells induce smooth muscle cell chemotaxis via platelet-derived growth factor-BB and interleukin-1alpha.

Authors:  Alan Dardik; Akimasa Yamashita; Faisal Aziz; Hidenori Asada; Bauer E Sumpio
Journal:  J Vasc Surg       Date:  2005-02       Impact factor: 4.268

6.  Expansive remodeling is a response of the plaque-related vessel wall in aortic roots of apoE-deficient mice: an experiment of nature.

Authors:  Jacob F Bentzon; Gerard Pasterkamp; Erling Falk
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-02-01       Impact factor: 8.311

7.  Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice.

Authors:  Faten Merhi-Soussi; Brenda R Kwak; David Magne; Christos Chadjichristos; Marina Berti; Graziano Pelli; Richard W James; François Mach; Cem Gabay
Journal:  Cardiovasc Res       Date:  2005-06-01       Impact factor: 10.787

8.  Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice.

Authors:  Hirokazu Kirii; Tamikazu Niwa; Yasuhiro Yamada; Hisayasu Wada; Kuniaki Saito; Yoichiro Iwakura; Masahide Asano; Hisataka Moriwaki; Mitsuru Seishima
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-02-27       Impact factor: 8.311

9.  Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer.

Authors:  Suresh Kumar; Hiromitsu Kishimoto; Hui Lin Chua; Sunil Badve; Kathy D Miller; Robert M Bigsby; Harikrishna Nakshatri
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

Review 10.  Immunological and inflammatory functions of the interleukin-1 family.

Authors:  Charles A Dinarello
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

View more
  32 in total

Review 1.  Role of Heat Shock Protein 27 in Modulating Atherosclerotic Inflammation.

Authors:  Jose A Inia; Edward R O'Brien
Journal:  J Cardiovasc Transl Res       Date:  2020-07-13       Impact factor: 4.132

Review 2.  Adipokines, adiposity, and atherosclerosis.

Authors:  Longhua Liu; Zunhan Shi; Xiaohui Ji; Wenqian Zhang; Jinwen Luan; Tarik Zahr; Li Qiang
Journal:  Cell Mol Life Sci       Date:  2022-05-03       Impact factor: 9.261

Review 3.  Inflammasomes: a preclinical assessment of targeting in atherosclerosis.

Authors:  Jeremiah Stitham; Astrid Rodriguez-Velez; Xiangyu Zhang; Se-Jin Jeong; Babak Razani
Journal:  Expert Opin Ther Targets       Date:  2020-08-06       Impact factor: 6.902

4.  When, where, and how to target vascular inflammation in the post-CANTOS era?

Authors:  Pasquale Maffia; Tomasz J Guzik
Journal:  Eur Heart J       Date:  2019-08-07       Impact factor: 29.983

Review 5.  Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.

Authors:  Antonio Abbate; Stefano Toldo; Carlo Marchetti; Jordana Kron; Benjamin W Van Tassell; Charles A Dinarello
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

Review 6.  Targets and regulation of microRNA-652-3p in homoeostasis and disease.

Authors:  Maxwell T Stevens; Bernadette M Saunders
Journal:  J Mol Med (Berl)       Date:  2021-03-12       Impact factor: 4.599

7.  The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis.

Authors:  Trevor P Fidler; Chenyi Xue; Mustafa Yalcinkaya; Brian Hardaway; Sandra Abramowicz; Tong Xiao; Wenli Liu; David G Thomas; Mohammad Ali Hajebrahimi; Joachim Pircher; Carlos Silvestre-Roig; Andriana G Kotini; Larry L Luchsinger; Ying Wei; Marit Westerterp; Hans-Willem Snoeck; Eirini P Papapetrou; Christian Schulz; Steffen Massberg; Oliver Soehnlein; Benjamin Ebert; Ross L Levine; Muredach P Reilly; Peter Libby; Nan Wang; Alan R Tall
Journal:  Nature       Date:  2021-03-17       Impact factor: 69.504

Review 8.  Anti-inflammatory and Immunomodulatory Therapies in Atherosclerosis.

Authors:  Justine Deroissart; Florentina Porsch; Thomas Koller; Christoph J Binder
Journal:  Handb Exp Pharmacol       Date:  2022

9.  Age and Interleukin-15 Levels Are Independently Associated With Intima-Media Thickness in Obesity-Related NAFLD Patients.

Authors:  Giovanni Tarantino; Vincenzo Citro; Clara Balsano; Domenico Capone
Journal:  Front Med (Lausanne)       Date:  2021-05-21

Review 10.  Inflammasomes as therapeutic targets in human diseases.

Authors:  Yangxin Li; Hui Huang; Bin Liu; Yu Zhang; Xiangbin Pan; Xi-Yong Yu; Zhenya Shen; Yao-Hua Song
Journal:  Signal Transduct Target Ther       Date:  2021-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.